Cyclerion Therapeutics, Inc. CYCN · Stock Open Cyclerion Therapeutics, Inc. in new tab
Cyclerion Therapeutics, Inc. Analysis (CYCN)
Is Cyclerion Therapeutics, Inc. a good investment? Cyclerion Therapeutics, Inc. (CYCN) is currently trading at 3.49 USD.
Earnings Schedule: Cyclerion Therapeutics, Inc. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is -1.31.
Investor FAQ
Does Cyclerion Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Cyclerion Therapeutics, Inc.?
Cyclerion Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of -1.31.
Company Profile
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| May 16, 2023 | 0.050000 |
Community Discussion